Niva Bupa Health Insurance Company concluded its 18th Annual General Meeting (AGM) on August 12, 2026, via video conferencing. Shareholders approved the audited financial statements for the fiscal year ended March 31, 2026, alongside several board appointments and executive compensation adjustments.

The joint statutory auditors, S. R. Batliboi & Co. LLP and Nangia & Co. LLP, issued reports on the financial statements without any qualifications, observations, or adverse remarks for FY26. Consequently, these reports were not read out during the meeting.

Board Appointments and Reappointments

Shareholders approved the following director-related resolutions:

• Reappointment by Rotation: Mr. Vishwanath Mahendra (Executive Director & CFO) and Mr. Ankur Kharbanda (Executive Director & Deputy CEO) were reappointed as they retired by rotation.
• Independent Director: Mr. Ashwani Bhatia was appointed as an Independent Director. His remuneration in the form of profit-related commission was also approved.
• Non-Executive Directors: Ms. Siobhan Djihan Moynihan and Mr. Christopher Patrick Carroll were appointed as Non-Executive Directors.

Mr. Roger William John Davis, a Non-Executive Director, was unable to attend due to personal exigency.

Executive Remuneration Revisions

The AGM approved revisions in remuneration for the financial year 2026-27 for three key executives:

Auditor Fees

The meeting approved the audit remuneration for the Joint Statutory Auditors for FY27:

• S. R. Batliboi & Co. LLP
• Nangia & Co. LLP

Meeting Proceedings

Mr. Ashwani Bhatia, Chairperson and Independent Director, presided over the meeting. Ms. Geeta Dutta Goel, Independent Director, chaired the proceedings for the special resolutions regarding Mr. Bhatia’s appointment and remuneration to ensure compliance with regulatory norms.

The Chairperson addressed members on the company’s business performance during FY26. A Q&A session facilitated by a moderator allowed 10 speakers to raise queries, which were addressed by Mr. Krishnan Ramachandran. Remote e-voting commenced on August 9, 2026, and concluded on August 11, 2026.

Niva Bupa Health Insurance Company company name has secured regulatory approval from the Insurance Regulatory and Development Authority of India (IRDAI) for the appointment of Ashwani Bhatia as its Chairperson. The IRDAI granted this approval via a letter dated August 10, 2026, confirming that Mr. Bhatia’s tenure begins retroactively from June 3, 2026. This development finalizes the leadership transition previously intimated by the company, ensuring compliance with insurance sector governance norms.

The appointment follows an application submitted by the company to the IRDAI. In a disclosure filed with stock exchanges on August 11, 2026, Niva Bupa referenced its earlier intimation dated June 3, 2026, regarding the proposed change in chairmanship. The regulatory nod validates the board’s decision and allows the company to proceed with formalizing Mr. Bhatia’s role without further regulatory hurdles.

Key Appointment Details

Ashwani Bhatia, identified by Director Identification Number (DIN) 07423221, assumes the chairmanship effective June 3, 2026. The retrospective effective date aligns with the initial intimation provided to market regulators, ensuring continuity in corporate governance records during the interim period between the board’s decision and regulatory confirmation.

The disclosure was signed by Aparna Sharma, Company Secretary and Compliance Officer of Niva Bupa Health Insurance Company Limited. The filing was submitted to both the National Stock Exchange of India Limited and BSE Limited under reference number NIVABUPA/EQ/2026-27/32. This procedural step ensures transparency and keeps investors informed about material changes in the company’s leadership structure.

What This Means for Governance

The timely receipt of IRDAI approval underscores the company’s adherence to regulatory protocols governing senior management appointments in the insurance sector. With Ashwani Bhatia formally recognized as Chairperson, Niva Bupa can focus on strategic initiatives under stable leadership. The alignment between the effective date and the initial announcement suggests no disruption in decision-making processes during the regulatory review period.